Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nucleic acid ligands to the prostate specific membrane antigen

a prostate specific and nucleic acid ligand technology, applied in the direction of group 3/13 element organic compounds, peptides, drug compositions, etc., can solve the problems of limited use of proteins as drugs and reagents, and no reported rna aptamers to membrane bound tumor antigens, etc., to inhibit native psma enzymatic activity and high affinity

Inactive Publication Date: 2005-07-21
GILEAD SCI INC
View PDF1 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods for identifying and producing nucleic acid ligands that specifically bind to the Prostate Specific Membrane Antigen (PSMA). These ligands can be used clinically to inhibit the enzymatic activity of PSMA or can be modified to carry agents for imaging or delivery of therapeutic agents to prostate cancer cells. The invention is the first application of the SELEX process to a membrane tumor antigen. The unique aptamer sequences described in the invention have high affinity to PSMA and can be used as inhibitors of native PSMA enzymatic activity.

Problems solved by technology

The use of proteins as drugs and reagents is often limited by the activity of proteases, the size of the protein, transport and the ability of an organism to make antibodies against that protein.
Despite the success of this technique, however, there are no reported RNA aptamers to membrane bound tumor antigens.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleic acid ligands to the prostate specific membrane antigen
  • Nucleic acid ligands to the prostate specific membrane antigen
  • Nucleic acid ligands to the prostate specific membrane antigen

Examples

Experimental program
Comparison scheme
Effect test

example 1

Use of SELEX to Obtain Nucleic Acid Ligands to PSMA

Materials and Methods

[0087] Cloning PSMA cDNA from LNCaP.

[0088] First strand cDNA was synthesized from 2 μg total LNCaP RNA using Superscript II RNase H Reverse Transcriptase (Life Technologies, Inc). Primers homologous to PSMA cDNA bases 134-152 and 2551-2567, flanking the entire full-length PSMA coding region, were used for PCR amplification. Amplification was performed using high fidelity Pfu DNA Polymerase (Stratagene, La Jolla, Calif.). The isolated product was ligated into the pCR-2.1 vector (Invitrogen Corporation, Carlsbad, Calif.). One successful clone, pFULPSM-1, was sequenced and found identical to Genbank accession number M99487. This clone represents the coding region for the full length PSMA protein

[0089] Preparation of Recombinant PSMA Expressing Baculovirus.

[0090] Primers containing restriction enzyme cut sites were designed to overlap the sequence of the entire extracellular portion of PSMA plus a linking glyc...

example 2

Determination of Minimal Size of Aptamers A10 and A9

[0112] To determine minimal aptamer sequences, a series of 3′ and 5′ truncations were tested for IC50. Five nucleotides could be removed from the 3′ end of aptamer xPSM-A9 (SEQ ID NO:5) with retention of activity, yielding aptamer A9-1 (SEQ ID NO:6). It was found that at least 15 nucleotides could be deleted from the 3′ end of aptamer xPSM-A10 (SEQ ID NO:15) with retention of activity, yielding aptamer A10-3 (SEQ ID NO:18). This 18.5 kD aptamer retains the ability to inhibit xPSM NAALADase activity with a KI of 20.5 nM. (FIG. 8). The shorter A10-3 could not survive 5′-truncation.

TABLE 1RoundSignal / Noise13.4226.8315.8425.75125.065688.0

[0113]

TABLE 2Reaction mixtures for reverse transcription (RT), QPCR and Transcription5X RT mixQPCR mixTranscription mix2.5 μL 10X RT buffer 10 μL 10X SQ buffer40 μL 5X nucleotides  1 μL 25 mM dNTP′S  1 μL 3′ primer 100 μM40 μL 5X Ribomax  1 μL H2O0.5 μL 5′ primer 100 μM10 μL guanosine 100 mM0.5 μL A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Methods are provided for generating nucleic acid ligands of Prostate Specific Membrane Antigen (PSMA). The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to PSMA, and methods and compositions for the treatment and diagnosis of disease using the nucleic acid ligands.

Description

RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 09 / 978,969, filed Oct. 16, 2001, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 278,830, filed Mar. 26, 2001 “Nucleic Acid Ligands to the Prostate Specific Membrane Antigen” and which also claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 240,781, filed Oct. 16, 2000, entitled “Nucleic Acid Ligands to the Prostate Specific Membrane Antigen”. Each of the aforementioned applications is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] Described herein are high affinity nucleic acid ligands to Prostate Specific Membrane Antigen (PSMA). Also described herein are methods for identifying and preparing high affinity nucleic acid ligands to PSMA. The method used herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by Exponential enrichment. Further disclosed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/09A61K47/48A61K51/00A61P35/00C07K14/705C07K17/02C12N15/115C12Q1/68
CPCC07K14/705C12Q1/6886C12N2310/322C12N15/115A61P35/00
Inventor LUPOLD, SHAWNLIN, YUNHICKE, BRIANCOFFEY, DONALD
Owner GILEAD SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com